SB 436 In Committee
Drugs, Prescription - As enacted, adds mandating the use of biosimilar drugs as a cost-saving measure the bureau of TennCare may implement; adds that a health carrier, health benefit plan, or utilization review organization may require a patient to try a biosimilar product prior to providing coverage for the equivalent branded prescription drug; requires the TennCare pharmacy advisory committee to consider as a factor the use of biosimilar drugs in the committee's recommendation to the bureau of TennCare on any drugs to be added to the state preferred drug list. - Amends TCA Title 4; Title 53; Title 56; Title 68 and Title 71.
Introduced
In Committee
Floor
Crossed Over
Passed
Enacted
No summary has been published for this bill. The full text is on the Bill text tab.
- Chamber
- Senate
- Introduced
- Jan 28, 2025
- Last action
- Apr 28, 2025 — Comp. became Pub. Ch. 206
- Session
- 114
- Momentum
- 31 · Low